← GLP-1 receptor agonists × body weight & composition

TrialDiabetes, obesity & metabolism2016

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.

T S Bailey et al.PubMed ↗Full text ↗Publisher ↗

The primary results report of NCT01907854. Its numbers are set against the trial’s posted results below.

Liraglutidelooks good hereLower HbA1c from baseline to week 26, lower body weight.Randomised, small.

What the trial testedrandomised · 407 people · 2016

Randomised vs continued sitagliptin

Probably lowered HbA1c from baseline to week 26

Doesn’t vote: same as the registry's posted result, which counts instead

−0.61percentage points−0.82 to −0.40

liraglutide vs continued sitagliptin

As reported

difference −0.61 %, 95% CI −0.82 to −0.40 · the paper's word: change in HbA1c from baseline to week 26

Randomised vs continued sitagliptin

Probably lowered body weight

Doesn’t vote: same as the registry's posted result, which counts instead

−1.67kg−2.34 to −0.99

liraglutide vs continued sitagliptin

As reported

difference −1.67 kg, 95% CI −2.34 to −0.99 · the paper's word: change in body weight

Against the trial’s posted results

Same as the trial’s posted resultThis paper difference −1.67 (−2.34 to −0.99)Posted difference −1.67 (−2.34 to −0.99), p <0.0001Change in Body Weight
Same as the trial’s posted resultThis paper difference −0.61 (−0.82 to −0.40)Posted, primary outcome difference −0.61 (−0.82 to −0.40), p <0.0001Change in HbA1c (Glycosylated Haemoglobin)

Who was studied, and how

407people with obesity, in this paper

The trial randomly assignedassigned by chance

liraglutide

continued sitagliptin

Probably lowered HbA1c from baseline to week 26−0.61

Probably lowered body weight−1.67

randomised

the abstract, start to end

… mean treatment difference (ETD): -0.61% (95% CI -0.82 to -0.40; …

… liraglutide [-3.31 kg vs. -1.64 kg; ETD: -1.67 kg (95% CI -2.34 to -0.99; …

← favours treatmentfavours comparator →

could be chance

Change in HbA1c from baseline to week 26liraglutide vs continued sitagliptin

−0.61−0.82 to −0.40

Change in body weightliraglutide vs continued sitagliptin

−1.67−2.34 to −0.99

GLP-1 receptor agonistsGlycemic controlBody weight & composition

1 / 4

21 papers cite it

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it

The trial

NCT01907854phase 4407 enrolled2013this paper is its primary report